SINGLE-CELL TRANSCRIPTOMICS AND EPIGENOMICS POINT TO CD58-CD2 INTERACTION IN CONTROLLING PRIMARY MELANOM GROWTH AND IMMUNITY
written by Antonia Stubenvoll, Maria Schmidt, Johanna Moeller, Max Alexander Lingner Chango, Carolyn Schultz, Olga Antoniadou, Henry Loeffler-Wirth, Stephan Bernhart, Florian Große, Beatrice Thier, Annette Paschen, Ulf Anderegg, Jan C Simon, Mirjana Ziemer, Clara T Schoeder, Hans Binder, Manfred Kunz
Immunotherapy is currently one of the most promising treatment options for malignant melanoma [1]. To uncover new immunological targets for future treatment approaches, single-cell transcriptomic and epigenomic analyses were performed on human primary melanoma (MM) and melanocytic nevus (Nev) samples (Figure 1A). The detailed methods of this study are described in the Supplementary Material.
. . .
to read the full article, click here: https://onlinelibrary.wiley.com/doi/10.1002/cac2.12651